Topical psoriasis therapy remains constrained by poor skin penetration and the instability of bioactive compounds. A new preclinical study tested whether encapsulating perilla essential oil in a nanoemulsion could overcome these barriers and, when combined with curcumin, produce additive anti-inflammatory and barrier-repair effects in a murine psoriasis model.1
Psoriasis affects roughly 2 to 3 percent of the global population and is driven by keratinocyte hyperproliferation, dysregulated cytokine signalling, and epidermal barrier breakdown. Existing topical agents, including corticosteroids and vitamin D analogues, carry well-documented limitations in long-term use. Interest in naturally derived compounds has grown, but most candidates suffer from chemical instability or inadequate dermal penetration. Perilla essential oil (PO), derived from Perilla frutescens, contains long-chain fatty acids and lipid metabolites with reported anti-inflammatory properties, yet its volatility has historically limited practical application.1
What the study did
Zhang and colleagues developed PO-based nanoemulsions (PO-NEs) using gas chromatography-mass spectrometry (GC-MS) to characterise the oil's composition, confirming a fatty acid-dominant profile relevant to cutaneous inflammation and epidermal repair.1 In vitro work in keratinocytes showed that PO-NEs inhibited cell proliferation, reduced expression of key proinflammatory cytokines, and lowered intracellular reactive oxygen species (ROS) accumulation.1
The central in vivo experiment applied 5% PO-NE topically to a mouse model of imiquimod-induced psoriasis. Treated animals showed marked improvements in erythema and scaling scores, reduced epidermal hyperplasia, and decreased inflammatory cell infiltration compared with controls.1 RNA sequencing of lesional skin demonstrated broad transcriptional reprogramming, with pathway enrichment in extracellular matrix organisation, epidermal differentiation, and immune regulation.1 Of particular mechanistic interest, PO-NE produced pronounced suppression of Wnt/beta-catenin signalling, a pathway implicated in keratinocyte proliferation; this finding was validated by targeted qRT-PCR.1
Building on that carrier platform, the team encapsulated curcumin into PO-NE (Cur@PO-NE) and ran a head-to-head comparison against a curcumin suspension and curcumin loaded into medium-chain triglyceride (MCT) nanoemulsions. Cur@PO-NE produced superior skin permeation and intradermal deposition relative to both comparators, and generated the most pronounced improvements across clinical scores, histopathology, and inflammatory readouts.1 Local and systemic safety assessments indicated good tolerability and biocompatibility, though the study did not specify the duration or frequency of safety monitoring beyond the experimental period.1
Several limitations apply. All efficacy data derive from a murine imiquimod model, which approximates but does not fully replicate human plaque psoriasis pathophysiology. No quantitative effect sizes, p-values, or confidence intervals are reported in the abstract, preventing independent appraisal of the magnitude of effects. The study did not include a head-to-head comparison against any licensed topical psoriasis therapy. Human pharmacokinetic, tolerability, and efficacy data are entirely absent. The leap from this model to clinical application will require substantial further work.
The most immediate consequence of this paper is not a change in practice; it is a reminder of how wide the gap remains between a mechanistically interesting preclinical result and a usable topical therapy. Wnt/beta-catenin suppression is a credible target in psoriasis biology, and a natural-oil nanoemulsion that can reach the dermis with acceptable tolerability is a legitimate delivery challenge worth solving. But this study provides no p-values, no effect sizes, no comparison against calcipotriol or a mid-potency corticosteroid, and no human data whatsoever. The absence of quantitative reporting in the abstract is itself a quality signal clinicians should note.
For the dermatology pharmaceutical market, this kind of preclinical work feeds a pipeline of cosmeceutical and nutraceutical-adjacent products that often bypass the rigour of a regulated IND pathway. Companies operating in the topical biologics and small-molecule space, including those developing tapinarof or roflumilast cream, will watch natural-compound nanoformulation research with commercial curiosity but limited competitive anxiety at this stage. The real pressure would only begin if a Phase II trial demonstrated non-inferiority to a licensed agent, which this paper does not claim and does not test. NICE and EMA have no basis on which to act here.
Patients with mild-to-moderate psoriasis who are already seeking alternatives to steroids will encounter this kind of research amplified on patient forums long before it has been tested in a single human being. That translation lag is a practical problem for GPs and dermatologists who will field questions about perilla oil products available over the counter. The honest answer is that the mechanistic rationale is plausible, the mouse data are encouraging in direction if not in precision, and there is currently no clinical evidence to support recommending or dismissing these formulations. Holding that line, politely and repeatedly, remains the clinical task.
- The Pivot Perilla essential oil, previously limited by volatility and poor stability, was stabilised in a nanoemulsion formulation that retained its anti-inflammatory and barrier-modulating activity in a mouse psoriasis model.
- The Data Topical 5% perilla oil nanoemulsion (PO-NE) markedly improved erythema and scaling scores, reduced epidermal hyperplasia, and suppressed Wnt/beta-catenin signalling in imiquimod-induced psoriatic mice; curcumin-loaded PO-NE (Cur@PO-NE) outperformed both curcumin suspension and curcumin-in-MCT nanoemulsion on clinical, histological, and inflammatory readouts.1
- The Action No practice change is warranted. This is preclinical data only. Clinicians managing psoriasis should continue to follow established topical and systemic therapy guidelines pending human trial evidence.
Cite This Article
Team TLSFE. Perilla oil nanoemulsion improves psoriasis scores in mouse model. The Life Science Feed. Published May 17, 2026. Updated May 19, 2026. Accessed May 22, 2026. https://thelifesciencefeed.com/articles/perilla-oil-nanoemulsion-psoriasis-mouse-model.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
1. Zhang Z, Mu J, Tao S. Development of perilla essential oil-based nanoemulsions as anti-psoriatic and dermal delivery platforms for topical therapy. Int J Pharm X.
2026. PMID: 42023067.